Transient vision and intraocular pressure changes following anti-vascular endothelial growth factor injection
Canadian Journal of Ophthalmology · 2025
DOI: 10.1016/j.jcjo.2025.09.005 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Canadian Journal of Ophthalmology, 2025. Verfasst von Khaldon Abbas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ivey Eye Institute, St. Joseph's Health Care Centre, London, ON, Canada; Department of Ophthalmology and Visual Sciences, University of Western Ontar…. Hauptthemen laut MEDLINE: Intraocular Pressure, Angiogenesis Inhibitors, Visual Acuity, Recombinant Fusion Proteins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVE: To assess transient intraocular pressure (IOP) and visual acuity (VA) changes following anti-vascular endothelial growth factor (anti-VEGF) injections and explore factors influencing recovery. DESIGN: A prospective observational study. PARTICIPANTS: Eighty-six patients (100 eyes) receiving anti-VEGF injections with either aflibercept, bevacizumab, or ranibizumab at a retina clinic were included. METHODS: Age, biological sex, diagnosis (neovascular age-related macular degeneration, retinal vein occlusion, diabetic macular edema), antiseptic used, anti-VEGF agent, glaucoma status, and IOP-lowering pretreatment were collected. IOP and VA using Snellen charts were measured at baseline, 1, 10, 20, and 30 minutes after injection. Spearman's correlation coefficients were used to assess the relationships between IOP and VA. Ordinal logistic regression was used to evaluate predictors of delayed VA recovery. RESULTS: At 1 minute after intravitreal injection (IVI), VA worsened significantly from a baseline of 0.29 ± 0.21 to 0.76 ± 0.65 logMAR (p < 0.001), while IOP rose from 14.34 ± 4.39 mm Hg to 54.53 ± 20.21 mm Hg (p < 0.001). VA progressively improved over time, with 43% of eyes returning to baseline at 1 minute, 67% at 10 minutes, 83% at 20 minutes, and 89% at 30 minutes. The Spearman correlation coefficient for VA and IOP was statistically significant at 1-minute follow-up after IVI at 0.244 (p = 0.014) but not at later follow-ups. Eyes returning to baseline VA at 1 minute exhibited lower IOP than those not at baseline (p = 0.0004). Logistic regression revealed no significant predictors of delayed VA recovery. CONCLUSIONS: Worsened VA and elevated IOP are common in the immediate postinjection period with later improvement. Patients' awareness of VA fluctuations within the first 30 minutes postinjection may aid in the early detection and management of complications associated with IOP elevation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ivey Eye Institute, St. Joseph's Health Care Centre, London, ON, Canada; Department of Ophthalmology and Visual Sciences, University of Western Ontario, London, ON, Canada. Electronic address: kabbas6@uwo.ca.
- Ivey Eye Institute, St. Joseph's Health Care Centre, London, ON, Canada; Department of Ophthalmology and Visual Sciences, University of Western Ontario, London, ON, Canada.
- Ivey Eye Institute, St. Joseph's Health Care Centre, London, ON, Canada.
Zitieren
APA
Abbas, K., Basilious, A., Duncan, J., Sheidow, T., Hooper, P., & Gonder, J. (2025). Transient vision and intraocular pressure changes following anti-vascular endothelial growth factor injection. Canadian Journal of Ophthalmology. https://doi.org/10.1016/j.jcjo.2025.09.005
Vancouver
Abbas K, Basilious A, Duncan J, Sheidow T, Hooper P, Gonder J. Transient vision and intraocular pressure changes following anti-vascular endothelial growth factor injection. Canadian Journal of Ophthalmology. 2025. doi:10.1016/j.jcjo.2025.09.005
BibTeX
@article{Abbas2025,
author = {Abbas, Khaldon and Basilious, Amy and Duncan, Julie and Sheidow, Thomas and Hooper, Philip and Gonder, John},
title = {Transient vision and intraocular pressure changes following anti-vascular endothelial growth factor injection},
journal = {Canadian Journal of Ophthalmology},
year = {2025},
doi = {10.1016/j.jcjo.2025.09.005}
}
EUVIMED